BioCardia (BCDA) CEO Peter Altman adds 4,300 shares in July 2026 buying

Rhea-AI Filing Summary

BioCardia, Inc. President and CEO Peter Altman reported open-market purchases of company common stock. He bought 2,800 shares at $0.88 on July 14, 2026 and 1,500 shares at $0.86 on July 15, 2026, bringing his direct holdings to 368,385 shares. The reported prices reflect weighted averages of multiple trades executed between $0.86 and $0.89 per share.

Insider Trade Summary

Net Buyer: 4,300 shares ($3,754)

Net Buy 2 txns

Insider Altman Peter

Role President and CEO

Bought 4,300 shs ($4K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,500	$0.86	$1K
Purchase	Common Stock	2,800	$0.88	$2K

Holdings After Transaction: Common Stock — 368,385 shares (Direct)

Footnotes (1)

1. This transaction was executed in multiple trades ranging from $0.86 to $0.89 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price. This transaction was executed in multiple trades ranging from $0.86 to $0.89 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

Key Figures

Shares purchased 2026-07-14: 2,800 shares Shares purchased 2026-07-15: 1,500 shares Total shares purchased: 4,300 shares +4 more

7 metrics

Shares purchased 2026-07-14 2,800 shares Open-market purchase of BioCardia common stock at weighted average $0.88 per share

Shares purchased 2026-07-15 1,500 shares Open-market purchase of BioCardia common stock at weighted average $0.86 per share

Total shares purchased 4,300 shares Sum of reported open-market purchases on July 14 and 15, 2026

Holdings after transactions 368,385 shares Direct ownership of BioCardia common stock following the July 2026 purchases

Purchase price 2026-07-14 $0.88 per share Weighted average price for the 2,800-share open-market purchase

Purchase price 2026-07-15 $0.86 per share Weighted average price for the 1,500-share open-market purchase

Trade price range $0.86–$0.89 per share Range of individual trade prices underlying each reported weighted average

Key Terms

open market or private transaction, weighted average per share sales price, Reporting Person

3 terms

open market or private transaction financial

"Purchase in open market or private transaction"

weighted average per share sales price financial

"The price reported above reflects the weighted average per share sales price."

Reporting Person regulatory

"The Reporting Person hereby undertakes to provide upon request"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/15/2026 - 04:41 PM Accepted by SEC EDGAR 07/15/2026 - 04:40 PM Learn about SEC filing dates

FAQ

What did BioCardia (BCDA) CEO Peter Altman report in this Form 4?

Peter Altman reported open-market purchases of BioCardia common stock totaling 4,300 shares over two days. He bought 2,800 shares at $0.88 on July 14, 2026 and 1,500 shares at $0.86 on July 15, 2026, all held directly.

How many BioCardia (BCDA) shares does Peter Altman own after these trades?

After the reported transactions, Peter Altman directly owns 368,385 shares of BioCardia common stock. This figure reflects his position following the purchase of 4,300 shares in July 2026 through two open-market transactions at weighted average prices of $0.88 and $0.86.

At what prices did the BioCardia (BCDA) CEO buy shares in this filing?

Altman’s reported weighted average purchase prices were $0.88 per share on July 14 and $0.86 on July 15. Footnotes state that each transaction involved multiple trades in a $0.86–$0.89 range, with the reported figures reflecting weighted average prices.

Were Peter Altman’s BioCardia (BCDA) trades open-market purchases?

Yes, both transactions are classified as open-market purchases of BioCardia common stock. The Form 4 identifies transaction code P and describes them as purchases in an open market or private transaction, reported as direct ownership by the President and CEO.

How many BioCardia (BCDA) shares did Peter Altman buy in total?

Altman bought a total of 4,300 shares of BioCardia common stock across two days. He acquired 2,800 shares on July 14, 2026 and 1,500 shares on July 15, 2026, all reported as directly owned following these open-market purchases.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/14/2026		P		2,800(1)	A	$0.88(1)	366,885	D
Common Stock	07/15/2026		P		1,500(2)	A	$0.86(2)	368,385	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $0.86 to $0.89 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

2. This transaction was executed in multiple trades ranging from $0.86 to $0.89 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

	/s/ David McClung, by power of attorney	07/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)